Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics Holdings Inc has demonstrated significant clinical progress with its ARCT-810 program, which showed statistically significant improvements in glutamine and 15N urea markers, alongside a noted increase in FEV1 in certain patients, suggesting potential benefits in treating rare diseases. Management highlighted successful execution in their cystic fibrosis and ornithine transcarbamylase deficiency programs during their Q4/FY25 earnings report, fostering optimism in their LUNAR LNP platform and mRNA purification technology, which are expected to drive future value across various indications. Additionally, ongoing engagement from key opinion leaders (KOLs), despite the interim readout's limitations, suggests a sustained interest and potential for future advancements in the therapeutic landscape.

Arcturus Therapeutics Holdings Inc. has encountered significant challenges in its clinical development, particularly with the disappointing interim Phase 2 data for ARCT-032, which failed to show a meaningful improvement in FEV1 and led to the removal of the asset from valuation models. This lack of efficacy, combined with the company's decision to delay clinical timelines and the removal of the LUNAR-COVID Vaccine Global Profit Share from projections, has resulted in substantial reductions to price targets. Analysts are increasingly concerned about potential safety issues, the efficacy of ongoing mRNA drug trials, and the company's ability to secure necessary funding for operations, which collectively contribute to an unfavorable outlook on the stock.